Aquinox Pharmaceuticals, which develops small-molecule therapies for inflammatory disorders, raised $18 million in a Series C funding round from investors including Pfizer and Johnson & Johnson's venture units. The firm says midstage trials of AQX-1125, its lead drug candidate, could begin within months in patients with chronic obstructive pulmonary disease and interstitial cystitis.

Full Story:

Related Summaries